Quartz·1 min read·medium
Novo Nordisk stock sinks after anti-inflammatory heart drug fails late-stage trial
✦AI Summary
Novo Nordisk's stock price declined following the failure of its experimental anti-inflammatory drug, ziltivekimab, in a late-stage clinical trial. The drug failed to show a significant reduction in cardiovascular events compared to a placebo in a study of over 6,300 patients.
The experimental anti-inflammatory drug ziltivekimab did not reduce major adverse cardiovascular events compared with a placebo in a study of more than 6,300 patients
businesshealthscience
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in